FIELD: chemistry.
SUBSTANCE: invention relates to the compound of general formula (I)
where R1 is selected from the group consisting of: H and C1-C6 alkyl, R2 represents OH, R3 is selected from the group consisting of: H, C1-C6 alkyl and halogen, radicals from R10 to R12 are independently selected from the group consisting of: OH, C1-C6 alkyl, C1-C6 alkoxy and halogen, R13 is selected from the group consisting of: OH, C1-C6 alkoxy, NH2, NHMe, NHEt, N(Me)2 and N(Et)2, R14 and R15 are independently selected from the group consisting of: H, C1-C6 alkyl and halogen, or R13 and one of R14 and R15 form following structure: 
Also, the invention relates to a method for producing said compound and a pharmaceutical composition based thereon.
EFFECT: new compounds and a pharmaceutical composition based on them have been obtained that can be used in medicine for treatment of cancer.
52 cl, 12 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
| SYNTHESIS AND ANTICANCER ACTIVITY OF DERIVATIVES OF ARYL AND HETEROARYL QUINOLINES | 2011 |
|
RU2584688C2 |
| PREPARATION AND USE OF KINASE INHIBITOR | 2016 |
|
RU2691401C2 |
| AROMATASE INHIBITORS | 2010 |
|
RU2572244C2 |
| ERBB RECEPTOR INHIBITORS | 2019 |
|
RU2810215C2 |
| JAK INHIBITOR COMPOUND AND USE THEREOF | 2020 |
|
RU2820445C2 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| COMPOSITIONS FOR PULMONARY FIBROSIS TREATMENT | 2017 |
|
RU2747801C2 |
| HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2764243C2 |
| SPLICEOSTATIN ANALOGS | 2013 |
|
RU2618523C2 |
